Holger Ottleben, PhD

Holger brings over 20 years of experience in Pharma, Biotech and Healthtech spanning multiple therapeutic areas and major elements of the value chain. He worked many years with Boehringer Ingelheim (BI) in different roles including Corporate VP Strategy and General Manager in European countries. Prior to joining BI, Holger was a core member of the Boston Consulting Groups Healthcare Practice. In addition, he has significant biotech start-up experience as co-founder of Graffinity AG / Santhera AG and has served as board member of VC-backed companies including Scienion AG, NBE Therapeutics AG, Amal Therapeutics SA, and Wellster Healthtech Group GmbH. Holger holds a Ph.D. in biochemistry.